Opus Genetics, Inc. (IRD) community

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30460% above fair value

$3.98−0.08 (-1.97%)

Close on Nov 13, 2026Market cap $331.12MP/E –Yield –

Community

Notes and questions about Opus Genetics from other investors

No posts about IRD yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Opus Genetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Nov 6, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IRD.

Compare: IRD vs TRDA · IRD vs PTN · IRD vs PRAX · IRD vs QURE · IRD vs XENE

Revenue growth-45.9% · median -93.5%

Operating margin-777.7% · median -2652.8%

Net margin-1726.7% · median -2606.4%

Company	Revenue	Growth
QURE	$20.17M	+28.0%
IRD	$7.91M	-45.9%
TRDA	$3.98M	-93.5%
PTN	–	–
PRAX	–	–
XENE	$0	-100.0%

Company

Next earnings (est.): Mar 9, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 27
Held by institutions: 72.8%
Auditor: Ernst & Young LLP
SEC CIK: 1228627

Advertisement
300 × 250

See a number that looks wrong?